Lorlatinib (2) (Lorviqua®) – Non-small cell lung cancer (NSCLC), ALK+, first-line

Characteristics

Start date 01.03.2022
Resolution 01.09.2022
INN Lorlatinib
Brand name Lorviqua®
Pharm. company Pfizer Pharma GmbH
G-BA procedure ID 2022-03-01-D-792
Therapeutic area Oncological diseases
Reason for procedure New Indication

G-BA resolution "Anwendungsgebiet des Beschlusses" (German)

Lorviqua as monotherapy is used to treat adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who have not been previously treated with an ALK inhibitor.

Subpopulation Indication Comparator
Adults with ALK-positive advanced non-small cell lung cancer (NSCLC) who have not previously been treated with an ALK inhibitor. Alectinib or Brigatinib

9. Associated procedures



<< List of all resolutions